These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 31068088)

  • 41. Regorafenib (Stivarga) for metastatic colorectal cancer and GIST.
    Med Lett Drugs Ther; 2013 Apr; 55(1415):e36. PubMed ID: 23836345
    [No Abstract]   [Full Text] [Related]  

  • 42. A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17.
    Yeh CN; Chen MH; Chen YY; Yang CY; Yen CC; Tzen CY; Chen LT; Chen JS
    Oncotarget; 2017 Jul; 8(27):44121-44130. PubMed ID: 28487491
    [TBL] [Abstract][Full Text] [Related]  

  • 43. miR-125a-5p regulation increases phosphorylation of FAK that contributes to imatinib resistance in gastrointestinal stromal tumors.
    Huang WK; Akçakaya P; Gangaev A; Lee L; Zeljic K; Hajeri P; Berglund E; Ghaderi M; Åhlén J; Bränström R; Larsson C; Lui WO
    Exp Cell Res; 2018 Oct; 371(1):287-296. PubMed ID: 30149002
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Story of Imatinib in GIST - a Journey through the Development of a Targeted Therapy.
    Reichardt P
    Oncol Res Treat; 2018; 41(7-8):472-477. PubMed ID: 29895025
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Duodenal gastrointestinal stromal tumor: From clinicopathological features to surgical outcomes.
    Marano L; Boccardi V; Marrelli D; Roviello F
    Eur J Surg Oncol; 2015 Jul; 41(7):814-22. PubMed ID: 25956211
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Imatinib Dosing in Gastrointestinal Stromal Tumors (GISTs): When, How Much, and How Long?
    Milhem M; Deutsch JM
    Curr Clin Pharmacol; 2015; 10(4):311-20. PubMed ID: 26548908
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [A case of recurrent duodenal gastrointestinal stromal tumor resistant to imatinib and sunitinib, successfully treated with regorafenib].
    Takeda Y; Nakahira S; Katsura Y; Ohmura Y; Kusama H; Kuroda Y; Goto T; Hashimoto T; Kimura K; Matsushita K; Sato Y; Morimoto Y; Ishida T; Nitta K; Kagawa Y; Okishiro M; Takeno A; Sakisaka H; Taniguchi H; Egawa C; Ohzono K; Nakatsuka S; Kato T; Tamura S
    Gan To Kagaku Ryoho; 2014 Nov; 41(12):1545-7. PubMed ID: 25731247
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment of gastrointestinal stromal tumor after imatinib and sunitinib.
    Montemurro M; Bauer S
    Curr Opin Oncol; 2011 Jul; 23(4):367-72. PubMed ID: 21519258
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Gastrointestinal stromal tumor (GIST) with liver metastases: An 18-year experience from the GIST cooperation group in North China.
    Shi YN; Li Y; Wang LP; Wang ZH; Liang XB; Liang H; Zhang L; Li B; Fan LQ; Zhao Q; Ma ZX; Zhao XF; Zhang ZD; Liu Y; Tan BB; Wang D; Wang LL; Hao YJ; Jia N
    Medicine (Baltimore); 2017 Nov; 96(46):e8240. PubMed ID: 29145240
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial.
    Mir O; Cropet C; Toulmonde M; Cesne AL; Molimard M; Bompas E; Cassier P; Ray-Coquard I; Rios M; Adenis A; Italiano A; Bouché O; Chauzit E; Duffaud F; Bertucci F; Isambert N; Gautier J; Blay JY; Pérol D;
    Lancet Oncol; 2016 May; 17(5):632-41. PubMed ID: 27068858
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Imatinib-resistant gastrointestinal stromal tumors in the era of second- and third-line tyrosine kinase inhibitors: Does surgical resection have a role?
    Sutton TL; Walker BS; Billingsley KG; Sheppard BC; Corless CL; Heinrich MC; Mayo SC
    Surgery; 2021 Nov; 170(5):1481-1486. PubMed ID: 34090672
    [TBL] [Abstract][Full Text] [Related]  

  • 52. GEIS guidelines for gastrointestinal sarcomas (GIST).
    Poveda A; García Del Muro X; López-Guerrero JA; Cubedo R; Martínez V; Romero I; Serrano C; Valverde C; Martín-Broto J;
    Cancer Treat Rev; 2017 Apr; 55():107-119. PubMed ID: 28351781
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Managing progressive disease in patients with GIST: factors to consider besides acquired secondary tyrosine kinase inhibitor resistance.
    Patel S
    Cancer Treat Rev; 2012 Aug; 38(5):467-72. PubMed ID: 22035971
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Proteogenomics for the Study of Gastrointestinal Stromal Tumors.
    Kondo T
    Adv Exp Med Biol; 2016; 926():139-151. PubMed ID: 27686810
    [TBL] [Abstract][Full Text] [Related]  

  • 55. KIT over-expression by p55PIK-PI3K leads to Imatinib-resistance in patients with gastrointestinal stromal tumors.
    Lai S; Wang G; Cao X; Luo X; Wang G; Xia X; Hu J; Wang J
    Oncotarget; 2016 Jan; 7(2):1367-79. PubMed ID: 26587973
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Current management of patients with gastrointestinal stromal tumor receiving the multitargeted tyrosine kinase inhibitor sunitinib.
    Pilotte AP
    Curr Med Res Opin; 2015; 31(7):1363-76. PubMed ID: 25912466
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inhibition of stromal-interacting molecule 1-mediated store-operated Ca
    Yang Z; Pan L; Liu S; Li F; Lv W; Shu Y; Dong P
    Cancer Sci; 2018 Sep; 109(9):2792-2800. PubMed ID: 29957833
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Significance of surgical treatment for recurrent and metastatic gastrointestinal stromal tumors].
    Zhang XH; He YL
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Sep; 23(9):840-844. PubMed ID: 32927506
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A Case of Disseminated Intra-abdominal Gastrointestinal Stromal Tumor Managed with Low Dose Imatinib.
    Jang BH; Kim BW; Lim KJ; Kim BG; Park SM; Kim JS; Ji JS; Choi H
    Korean J Gastroenterol; 2015 Jun; 65(6):366-9. PubMed ID: 26087692
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cytoreductive Surgery for Metastatic Gastrointestinal Stromal Tumors Treated With Tyrosine Kinase Inhibitors: A 2-institutional Analysis.
    Fairweather M; Balachandran VP; Li GZ; Bertagnolli MM; Antonescu C; Tap W; Singer S; DeMatteo RP; Raut CP
    Ann Surg; 2018 Aug; 268(2):296-302. PubMed ID: 28448384
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.